Petros Pharmaceuticals, Inc.
PTPI
$0.01
$0.0029.03%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -81.97% | -44.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -81.97% | -44.14% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -32.50% | -8.12% | 0.31% | -30.33% | -34.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.50% | -8.12% | 0.31% | -44.66% | -54.86% |
| Operating Income | 32.50% | 8.12% | -0.31% | 46.88% | 48.85% |
| Income Before Tax | 32.07% | -87.43% | -538.21% | -2,942.86% | -36.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 32.07% | -87.43% | -538.21% | -2,942.86% | -36.06% |
| Earnings from Discontinued Operations | 100.00% | 161.62% | 147.11% | 52.85% | -0.45% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 61.52% | 122.10% | 113.36% | -48.57% | -17.93% |
| EBIT | 32.50% | 8.12% | -0.31% | 46.88% | 48.85% |
| EBITDA | 101.50% | 39.84% | -0.80% | 66.48% | 67.20% |
| EPS Basic | 99.38% | 97.94% | 88.46% | 64.55% | 68.97% |
| Normalized Basic EPS | 98.52% | 96.23% | -190.11% | -157.89% | 89.75% |
| EPS Diluted | 99.38% | 97.94% | 88.46% | 64.55% | 68.97% |
| Normalized Diluted EPS | 98.52% | 96.23% | -190.11% | -157.89% | 89.75% |
| Average Basic Shares Outstanding | 539.63% | 6,857.17% | 8,612.66% | 7,062.83% | 4,088.34% |
| Average Diluted Shares Outstanding | 539.63% | 6,857.17% | 8,612.66% | 7,062.83% | 4,088.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |